- Home
- INTR vs BCRX Comparison
INTR vs BCRX Comparison
Compare INTR & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- BCRX
- Stock Information
- Founded
- INTR 1994
- BCRX 1986
- Country
- INTR Brazil
- BCRX United States
- Employees
- INTR N/A
- BCRX N/A
- Industry
- INTR
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INTR
- BCRX Health Care
- Exchange
- INTR Nasdaq
- BCRX Nasdaq
- Market Cap
- INTR 2.1B
- BCRX 1.7B
- IPO Year
- INTR N/A
- BCRX 1994
- Fundamental
- Price
- INTR $5.68
- BCRX $8.01
- Analyst Decision
- INTR Buy
- BCRX Buy
- Analyst Count
- INTR 4
- BCRX 6
- Target Price
- INTR $6.48
- BCRX $15.67
- AVG Volume (30 Days)
- INTR 3.8M
- BCRX 3.8M
- Earning Date
- INTR 05-07-2025
- BCRX 05-05-2025
- Dividend Yield
- INTR 1.43%
- BCRX N/A
- EPS Growth
- INTR 176.00
- BCRX N/A
- EPS
- INTR 0.33
- BCRX N/A
- Revenue
- INTR $743,862,312.00
- BCRX $450,712,000.00
- Revenue This Year
- INTR $81.95
- BCRX $27.66
- Revenue Next Year
- INTR $17.31
- BCRX $13.59
- P/E Ratio
- INTR $16.76
- BCRX N/A
- Revenue Growth
- INTR 43.28
- BCRX 36.00
- 52 Week Low
- INTR $3.88
- BCRX $4.03
- 52 Week High
- INTR $7.84
- BCRX $9.50
- Technical
- Relative Strength Index (RSI)
- INTR 53.88
- BCRX 50.00
- Support Level
- INTR $5.52
- BCRX $7.44
- Resistance Level
- INTR $6.08
- BCRX $8.12
- Average True Range (ATR)
- INTR 0.21
- BCRX 0.29
- MACD
- INTR -0.00
- BCRX 0.03
- Stochastic Oscillator
- INTR 56.70
- BCRX 86.96
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.